MicroRNA-21 Expression, Serum Tumor Markers, and Immunohistochemistry in Canine Mammary Tumors

Overview

Journal Vet Res Commun

Publisher Springer

Specialty Veterinary Medicine

Date 2021 Nov 17

PMID 34787777

Citations 10

Authors

Eman S Ramadan

Noha Y Salem

Ibrahim A Emam

Naglaa A AbdElkader

Haithem A Farghali

Marwa S Khattab

Affiliations

Soon will be listed here.

Abstract

Background: Canine mammary tumors (CMTs) are one of the most common malignancies in dogs and are associated with significant mortality. Serum tumor markers and non-coding microRNAs have gained widespread popularity in human oncology studies. The present study has two aims, first one is to investigate the miR-21 expression compared with changes in serum tumor markers (CEA and CA15-3) in CMT. The second aim is to detect the immunohistochemistry markers as vimentin, P63, and -SMA in CMT.

Methods: This study enrolled 17 female dogs: 10 with mammary tumors and seven controls without tumors. Blood samples were collected to measure miR-21, CEA, and CA 15-3, and histological samples were prepared for histological grading and immunohistochemistry.

Results: CA 15-3 was elevated in all animals, whereas CEA levels showed no change compared with controls. miR-21 was upregulated 12.84-fold in animals with CMT. The most frequently recorded CMT was the mixed type. Myoepithelial cells were identified by P63 immunoreactivity, but not SMA. High expression of miR-21 was observed with positive vimentin immunoreactivity, indicating the mesenchymal origin of the tumor cells.

Conclusion: The present study showed that miR-21 was elevated to a greater extent than CA 15-3 (12.84-fold vs. threefold). Tumors that was positive for vimentin immunoreactivity was also associated with an elevation in the levels of miR-21, showing that miR-21 is released from mesenchymal cells. These findings support the hypothesis that miR-21 may be a more sensitive, noninvasive indicator for CMT.

Citing Articles

Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors.

Ferreira T, Gil da Costa R, Dias F, Gama A, Gaspar V, Mano J Geroscience. 2024; 46(6):6641-6657.

PMID: 38954129 PMC: 11494623. DOI: 10.1007/s11357-024-01260-7.

Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier.

Gherman L, Tomuleasa D, Cismaru A, Nutu A, Berindan-Neagoe I Med Pharm Rep. 2024; 97(2):132-142.

PMID: 38746025 PMC: 11090284. DOI: 10.15386/mpr-2733.

Review of Molecular Technologies for Investigating Canine Cancer.

Kehl A, Aupperle-Lellbach H, de Brot S, van der Weyden L Animals (Basel). 2024; 14(5).

PMID: 38473154 PMC: 10930838. DOI: 10.3390/ani14050769.

Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas.

Tomanelli M, Florio T, Vargas G, Pagano A, Modesto P Life (Basel). 2023; 13(12).

PMID: 38137885 PMC: 10744527. DOI: 10.3390/life13122284.

A review on microRNA detection and expression studies in dogs.

Varvil M, Dos Santos A Front Vet Sci. 2023; 10:1261085.

PMID: 37869503 PMC: 10585042. DOI: 10.3389/fvets.2023.1261085.

References

Alexandrakis M, Passam F, Perisinakis K, Ganotakis E, Margantinis G, Kyriakou D . Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med. 2002; 96(8):553-8. DOI: 10.1053/rmed.2002.1328. View

Anastasov N, Hofig I, Vasconcellos I, Rappl K, Braselmann H, Ludyga N . Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol. 2012; 7:206. PMC: 3573984. DOI: 10.1186/1748-717X-7-206. View

Bautista-Sanchez D, Arriaga-Canon C, Pedroza-Torres A, De La Rosa-Velazquez I, Gonzalez-Barrios R, Contreras-Espinosa L . The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics. Mol Ther Nucleic Acids. 2020; 20:409-420. PMC: 7118281. DOI: 10.1016/j.omtn.2020.03.003. View

Blenkiron C, Goldstein L, Thorne N, Spiteri I, Chin S, Dunning M . MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007; 8(10):R214. PMC: 2246288. DOI: 10.1186/gb-2007-8-10-r214. View

Boggs R, Wright Z, Stickney M, Porter W, Murphy K . MicroRNA expression in canine mammary cancer. Mamm Genome. 2008; 19(7-8):561-9. DOI: 10.1007/s00335-008-9128-7. View

Bonnett B, Egenvall A, Hedhammar A, Olson P . Mortality in over 350,000 insured Swedish dogs from 1995-2000: I. Breed-, gender-, age- and cause-specific rates. Acta Vet Scand. 2005; 46(3):105-20. PMC: 1624819. DOI: 10.1186/1751-0147-46-105. View

Canadas A, Franca M, Pereira C, Vilaca R, Vilhena H, Tinoco F . Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study. Vet Pathol. 2018; 56(2):208-219. DOI: 10.1177/0300985818806968. View

Campos L, Lavalle G, Estrela-Lima A, Melgaco de Faria J, Guimaraes J, Dutra A . CA15.3, CEA and LDH in dogs with malignant mammary tumors. J Vet Intern Med. 2012; 26(6):1383-8. DOI: 10.1111/j.1939-1676.2012.01014.x. View

Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang B . miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 2013; 7(5):1579-84. DOI: 10.3892/mmr.2013.1403. View

10.

Chocteau F, Abadie J, Loussouarn D, Nguyen F . Proposal for a Histological Staging System of Mammary Carcinomas in Dogs and Cats. Part 1: Canine Mammary Carcinomas. Front Vet Sci. 2019; 6:388. PMC: 6854021. DOI: 10.3389/fvets.2019.00388. View

11.

Destexhe E, Lespagnard L, Degeyter M, Heymann R, Coignoul F . Immunohistochemical identification of myoepithelial, epithelial, and connective tissue cells in canine mammary tumors. Vet Pathol. 1993; 30(2):146-54. DOI: 10.1177/030098589303000207. View

12.

Dolka I, Sapierzynski R, Krol M . Retrospective study and immunohistochemical analysis of canine mammary sarcomas. BMC Vet Res. 2013; 9:248. PMC: 4029385. DOI: 10.1186/1746-6148-9-248. View

13.

Ebeling F, Stieber P, Untch M, Nagel D, Konecny G, Schmitt U . Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer. 2002; 86(8):1217-22. PMC: 2375330. DOI: 10.1038/sj.bjc.6600248. View

14.

Egenvall A, Bonnett B, Ohagen P, Olson P, Hedhammar A, von Euler H . Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med. 2005; 69(1-2):109-27. DOI: 10.1016/j.prevetmed.2005.01.014. View

15.

Eman S, Kubesy A, Baraka T, Torad F, Shaymaa I, Mohammed F . Evaluation of hepatocyte-derived microRNA-122 for diagnosis of acute and chronic hepatitis of dogs. Vet World. 2018; 11(5):667-673. PMC: 5993765. DOI: 10.14202/vetworld.2018.667-673. View

16.

Fish E, Martinez-Romero E, DeInnocentes P, Koehler J, Prasad N, Smith A . Circulating microRNA as biomarkers of canine mammary carcinoma in dogs. J Vet Intern Med. 2020; 34(3):1282-1290. PMC: 7255679. DOI: 10.1111/jvim.15764. View

17.

Mohammadi Ghahhari N, Babashah S . Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur J Cancer. 2015; 51(12):1638-49. DOI: 10.1016/j.ejca.2015.04.021. View

18.

Goldschmidt M, Pena L, Rasotto R, Zappulli V . Classification and grading of canine mammary tumors. Vet Pathol. 2011; 48(1):117-31. DOI: 10.1177/0300985810393258. View

19.

Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L . High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012; 507(2):135-8. DOI: 10.1016/j.gene.2012.07.025. View

20.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View